• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Alphabet, Ventas, ASML And A Pharmaceutical Giant On CNBC's 'Final Trades'

    6/5/24 9:28:27 AM ET
    $ASML
    $GOOG
    $GOOGL
    $PFE
    Industrial Machinery/Components
    Technology
    Computer Software: Programming Data Processing
    Technology
    Get the next $ASML alert in real time by email

    Jim Lebenthal of Cerity Partners named Alphabet Inc. (NASDAQ:GOOG) (NASDAQ:GOOGL) as his final trade on CNBC's “Halftime Report Final Trades.”

    Google by Alphabet, last week, declared a $2 billion investment plan to establish its inaugural data center and Google Cloud region in Malaysia.

    Jenny Van Leeuwen Harrington of Gilman Hill Asset Management, LLC said Ventas, Inc. (NYSE:VTR) has a 3.6% dividend yield.

    On May 1, Ventas reported better-than-expected first-quarter FFO and sales results. The company also reiterated its guidance.

    Don't forget to check out our premarket coverage here

    Stephen Weiss of Short Hills Capital Partners picked ASML Holding N.V. (NASDAQ:ASML).

    On April 17, ASML reported a fiscal first-quarter 2024 net sales of €5.29 billion, down 21.6% year-on-year. In USD, sales of $5.75 billion missed the consensus of $6.13 billion. Net bookings for the first quarter were €3.61 billion, compared to €3.75 billion a year ago, down from fourth-quarter net bookings of €9.19 billion.

    Joshua Brown of Ritholtz Wealth Management said Pfizer Inc. (NYSE:PFE) is breaking above its 50-day moving average for the first time in 18 months.

    On Friday, Pfizer released longer-term follow-up results from the Phase 3 CROWN trial evaluating Lorbrena (lorlatinib) available in Europe as Lorviqua versus Xalkori (crizotinib) in people with previously untreated, anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

    Price Action:

    • Ventas shares fell 0.1% to close at $50.00 on Tuesday.
    • Alphabet shares rose 0.4% to close at $175.13 during Tuesday's session.
    • ASML fell 1.5% to settle at $950.81 during Tuesday's session.
    • Pfizer shares rose 0.6% to close at $29.49 on Tuesday.

    Check This Out: Top 3 Tech And Telecom Stocks You May Want To Dump In June

    Image: Shutterstock

    Get the next $ASML alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASML
    $GOOG
    $GOOGL
    $PFE

    CompanyDatePrice TargetRatingAnalyst
    Pfizer Inc.
    $PFE
    2/12/2026$27.00Outperform → Neutral
    Daiwa Securities
    Alphabet Inc.
    $GOOG
    2/5/2026$400.00 → $420.00Buy
    Pivotal Research Group
    ASML Holding N.V. New York Registry Shares
    $ASML
    1/29/2026Equal Weight → Overweight
    Barclays
    Alphabet Inc.
    $GOOGL
    1/26/2026$330.00 → $360.00Overweight
    KeyBanc Capital Markets
    Alphabet Inc.
    $GOOGL
    1/23/2026$333.00 → $346.00Buy
    Stifel
    Alphabet Inc.
    $GOOG
    1/22/2026$400.00Outperform → Strong Buy
    Raymond James
    ASML Holding N.V. New York Registry Shares
    $ASML
    1/15/2026Outperform
    RBC Capital Mkts
    Alphabet Inc.
    $GOOG
    1/13/2026$350.00 → $355.00Buy
    TD Cowen
    More analyst ratings

    $ASML
    $GOOG
    $GOOGL
    $PFE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman and CEO Cafaro Debra A exercised 10,322 shares at a strike of $73.71 and sold $848,751 worth of shares (10,322 units at $82.23) (SEC Form 4)

    4 - Ventas, Inc. (0000740260) (Issuer)

    2/10/26 4:05:23 PM ET
    $VTR
    Real Estate Investment Trusts
    Real Estate

    Chief Executive Officer Pichai Sundar sold $10,893,259 worth of Class C Capital Stock (32,500 units at $335.18), was granted 1,348,607 units of Class C Capital Stock and covered exercise/tax liability with 676,955 units of Class C Capital Stock, increasing direct ownership by 29% to 2,851,024 units (SEC Form 4)

    4 - Alphabet Inc. (0001652044) (Issuer)

    2/6/26 7:36:40 PM ET
    $GOOGL
    Computer Software: Programming Data Processing
    Technology

    VP, Chief Accounting Officer O'Toole Amie Thuener sold $314,001 worth of Class C Capital Stock (933 units at $336.55), decreasing direct ownership by 9% to 9,916 units (SEC Form 4)

    4 - Alphabet Inc. (0001652044) (Issuer)

    2/3/26 6:50:39 PM ET
    $GOOGL
    Computer Software: Programming Data Processing
    Technology

    $ASML
    $GOOG
    $GOOGL
    $PFE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Pfizer downgraded by Daiwa Securities with a new price target

    Daiwa Securities downgraded Pfizer from Outperform to Neutral and set a new price target of $27.00

    2/12/26 7:23:25 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pivotal Research Group reiterated coverage on Alphabet with a new price target

    Pivotal Research Group reiterated coverage of Alphabet with a rating of Buy and set a new price target of $420.00 from $400.00 previously

    2/5/26 7:03:04 AM ET
    $GOOG
    Computer Software: Programming Data Processing
    Technology

    ASML upgraded by Barclays

    Barclays upgraded ASML from Equal Weight to Overweight

    1/29/26 6:57:57 AM ET
    $ASML
    Industrial Machinery/Components
    Technology

    $ASML
    $GOOG
    $GOOGL
    $PFE
    SEC Filings

    View All

    SEC Form FWP filed by Alphabet Inc.

    FWP - Alphabet Inc. (0001652044) (Subject)

    2/10/26 3:08:16 PM ET
    $GOOGL
    Computer Software: Programming Data Processing
    Technology

    SEC Form 424B5 filed by Alphabet Inc.

    424B5 - Alphabet Inc. (0001652044) (Filer)

    2/10/26 6:01:34 AM ET
    $GOOGL
    Computer Software: Programming Data Processing
    Technology

    Ventas Inc. filed SEC Form 8-K: Other Events

    8-K - Ventas, Inc. (0000740260) (Filer)

    2/9/26 8:32:10 AM ET
    $VTR
    Real Estate Investment Trusts
    Real Estate

    $ASML
    $GOOG
    $GOOGL
    $PFE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    10/11/24 2:12:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASML
    $GOOG
    $GOOGL
    $PFE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Blaylock Ronald E bought $499,072 worth of shares (19,457 units at $25.65), increasing direct ownership by 236% to 27,707 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    2/14/25 5:16:36 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Gottlieb Scott bought $28,240 worth of shares (1,000 units at $28.24), increasing direct ownership by 11% to 10,000 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    10/31/24 4:06:54 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gottlieb Scott bought $79,401 worth of shares (3,000 units at $26.47), increasing direct ownership by 50% to 9,000 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    12/19/23 9:31:01 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASML
    $GOOG
    $GOOGL
    $PFE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

    The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua

    2/11/26 5:31:00 PM ET
    $ABBV
    $AVBP
    $BDTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight

    The PROTAC market is experiencing rapid growth, driven by rising interest in targeted protein degradation as a next-generation therapeutic approach. Expanding oncology pipelines with drugs in clinical trials such as vepdegestrant (Arvinas and Pfizer), luxdegalutamide (Arvinas and Novartis), ASP3082 (Astellas Pharma), DT2216 (Dialectic Therapeutics), and others, along with increasing applicability in neurodegenerative and inflammatory diseases, are further fueling sustained R&D investment. LAS VEGAS, Feb. 10, 2026 /PRNewswire/ -- DelveInsight's PROTAC Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment prac

    2/10/26 5:31:00 PM ET
    $ARVN
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

    Submission is to expand HYMPAVZI indication to the treatment of hemophilia A or B patients 6 years and older with inhibitors, and pediatric patients (ages 6 to 11) without inhibitors If approved, HYMPAVZI would become the first non-factor prophylactic treatment available for children aged 6 to 11 years with hemophilia B Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company's supplemental Biologics License Application (sBLA) for HYMPAVZI® (marstacimab) to expand the approved indication to include the treatment of hemophilia A or B patients 6 years and older with inhibitors, and pediatric patient

    2/6/26 6:45:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASML
    $GOOG
    $GOOGL
    $PFE
    Financials

    Live finance-specific insights

    View All

    Ventas Reports Fourth Quarter and Full Year 2025 Results, Provides 2026 Outlook and Increases Dividend

    Ventas, Inc. (NYSE:VTR) ("Ventas" or the "Company") today reported results for the full year and fourth quarter ended December 31, 2025. CEO Remarks "Ventas delivered strong performance and enterprise growth in the fourth quarter and full year 2025. We executed our strategy to drive organic and external growth in senior housing and increased our participation in this multiyear growth opportunity," said Debra A. Cafaro, Ventas Chairman and CEO. "In 2025, we grew Same-Store Cash Net Operating Income ("NOI") by over 15% in our senior housing operating portfolio ("SHOP"). We capitalized on powerful secular demand trends and utilized our proprietary analytic and operational insights to del

    2/5/26 4:10:00 PM ET
    $VTR
    Real Estate Investment Trusts
    Real Estate

    Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance

    Focused Execution Drives Strong Full-Year 2025 EPS Performance Enters 2026 with Clear Strategic Priorities and Growing Late-Stage Pipeline Advanced 11 Key Pivotal Study Starts in 2025 and ~20 Key Pivotal Study Starts Planned for 2026 Pfizer Inc. (NYSE:PFE) reported financial results for fourth-quarter and full-year 2025 and reaffirmed its full-year 2026 financial guidance(1) provided on December 16, 2025. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "With excellent execution in 2025, we delivered a solid financial performance and strengthened Pfizer's foundation for future growth. Looking ahead, 2026 will be an important year rich in key catalysts, inc

    2/3/26 6:45:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ASML reports €32.7 billion total net sales and €9.6 billion net income in 2025

    ASML reports €32.7 billion total net sales and €9.6 billion net income in 2025ASML expects 2026 total net sales to be between €34 billion and €39 billion, with a gross margin between 51% and 53% VELDHOVEN, the Netherlands, January 28, 2026 – Today, ASML Holding NV (ASML) has published its 2025 fourth-quarter and full-year results. Q4 total net sales of €9.7 billion, gross margin of 52.2%, net income of €2.8 billionQuarterly net bookings in Q4 of €13.2 billion of which €7.4 billion is EUV2025 total net sales of €32.7 billion, gross margin of 52.8%, net income of €9.6 billionBacklog at the end of 2025 of €38.8 billionASML expects Q1 2026 total net sales between €8.2 billion and €8.9 billion

    1/28/26 1:00:00 AM ET
    $ASML
    Industrial Machinery/Components
    Technology

    $ASML
    $GOOG
    $GOOGL
    $PFE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ventas Inc.

    SC 13G - Ventas, Inc. (0000740260) (Subject)

    10/15/24 1:39:07 PM ET
    $VTR
    Real Estate Investment Trusts
    Real Estate

    SEC Form SC 13G/A filed by Alphabet Inc. (Amendment)

    SC 13G/A - Alphabet Inc. (0001652044) (Subject)

    2/14/24 5:02:00 PM ET
    $GOOGL
    Computer Software: Programming Data Processing
    Technology

    SEC Form SC 13G/A filed by Ventas Inc. (Amendment)

    SC 13G/A - Ventas, Inc. (0000740260) (Subject)

    2/13/24 5:16:09 PM ET
    $VTR
    Real Estate Investment Trusts
    Real Estate

    $ASML
    $GOOG
    $GOOGL
    $PFE
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    SOFR Academy Appoints R. Martin "Marty" Chávez as Senior Advisor

    SOFR Academy, Inc., a leading financial engineering firm, today announced the appointment of R. Martin "Marty" Chávez as Senior Advisor. Widely regarded as one of the most influential figures at the intersection of finance, technology, and data science, Mr. Chávez brings decades of leadership experience shaping modern financial markets and innovation ecosystems. He is a Partner and Vice Chairman at global investment firm Sixth Street, where he serves on the firm's Executive Committee and leads research and development initiatives focused on advanced software, artificial intelligence, and healthcare technology partnerships. Mr. Chávez also serves on the Board of Directors of Alphabet Inc. (N

    11/12/25 7:00:00 AM ET
    $GOOGL
    Computer Software: Programming Data Processing
    Technology

    ASML appoints next Chief Technology Officer

    ASML appoints next Chief Technology Officer Marco Pieters appointed ASML Chief Technology Officer ASML Supervisory Board intends to reappoint CFO Roger Dassen and COO Frédéric Schneider-Maunoury, and to appoint CTO Marco Pieters to the Board of Management as of the April 2026 AGM VELDHOVEN, The Netherlands, October 9, 2025 – ASML Holding NV (ASML) today announced the appointment of Marco Pieters as Executive Vice President and Chief Technology Officer, reporting to President and Chief Executive Officer, Christophe Fouquet. With over 25 years of experience at ASML, most recently as Executive Vice President for the product area Applications, Pieters has a strong track record in technology l

    10/9/25 2:00:00 AM ET
    $ASML
    Industrial Machinery/Components
    Technology